Clarivate PLC stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideWatch
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideToo few of the required measures on file
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWeak
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Discovery Gap: Very high (69/100) · Gap confidence 53/100
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideModerate 53/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideStrong 64/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Evidence timeline
- Expected
Wed 24 Feb · expected 10-K
Last year filed 24 Feb 2026.
Thu 29 Apr · expected 10-Q
Last year filed 29 Apr 2026.
- Filed
Tue 3 Nov · 8-K
8-K · Item 2.02 — Results of operations
Clarivate completed Q3 2026 earnings with improved organic recurring revenue growth (0.7%), positive ACV growth in IP segment (1.8%), and early close of LS&H divestiture ($488.4M proceeds). Updated 2026 guidance reflects portfolio transformation toward higher-margin recurring revenue base.
Recognition: Watch 31 → Watch 34More of the market is starting to notice.
The price trend strengthened.
Tue 3 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Recognition: Watch 31 → Watch 34More of the market is starting to notice.
The price trend strengthened.
Tue 6 Oct · 8-K
8-K · Items 2.01, 5.02, 8.01 — Acquisition or disposal of assets
Clarivate completed sale of Life Sciences & Healthcare segment to Altaris for $600M ($500M cash + $75M note + $25M deferred). Proceeds to reduce debt and strengthen balance sheet. Company now focused on Academia & Government and Intellectual Property segments.
News flow: Balanced 49 → Balanced 54Gap Low · 0 → Very high · 75The filings read more positively.
Progress is running ahead of attention.
Thu 24 Sep · 8-K
8-K · Item 8.01 — Other events
Recognition: Watch 40 → Watch 36Market attention has faded.
The price trend weakened.
Wed 23 Sep · 8-K
Thu 17 Sep · 8-K
Wed 29 Jul · 8-K
Wed 29 Jul · 8-K
Wed 29 Jul · 10-Q
Mon 6 Jul · 8-K
Mon 6 Jul · 8-K
Mon 8 Jun · 8-K
Mon 18 May · 8-K
Wed 29 Apr · 8-K
Wed 29 Apr · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Thu 26 Mar · 8-K
Tue 24 Feb · 10-K
Annual report (10-K), FY2026
Tue 24 Feb · 8-K
Tue 3 Feb · 8-K
Mon 2 Feb · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.